Atrial fibrillation

Articolo redatto e revisionato del Dott. Luca Moretti

Atrial fibrillation is a supraventricular tachyarrhythmia characterized by disorganized atrial electrical activation and loss of coordinated atrial contraction. On the electrocardiogram, recognizable repetitive P waves are absent and, when atrioventricular conduction is preserved, RR intervals are irregular. Ventricular irregularity is a consequence of conduction through the atrioventricular node, not the definition of the atrial process: complete block or ventricular pacing may produce a regular rhythm while the atria continue to fibrillate.

It is the most common sustained arrhythmia in clinical practice. The likelihood of developing it increases with age, hypertension, obesity, heart failure, valvular disease, and genetic predisposition; its prevalence is also rising because people live longer with cardiovascular disease and because monitoring identifies episodes that previously went undetected. Incidence, prevalence, and cumulative risk are not interchangeable: they vary according to population age, duration of observation, and recording method. A diagnosis in a young person without evident heart disease and one in an older patient with multiple comorbidities describe the same electrical phenotype, but not necessarily the same underlying disease.

Its clinical relevance includes symptoms, functional deterioration, heart failure, and thromboembolism. Some patients immediately recognize every episode; in others, the first manifestation is a stroke or ventricular dysfunction. The intensity of palpitations alone does not measure risk, and restoration of sinus rhythm does not automatically resolve thrombotic vulnerability or atrial cardiomyopathy. Management therefore requires parallel interventions on the substrate, rate or rhythm, and embolic prevention.

Compared with other atrial arrhythmias, the distinguishing feature is the absence of stable, organized global activation attributable to a single focus or a macroscopic circuit. This distinction does not exclude transitions to flutter or atrial tachycardias, nor does it imply that the entire myocardium displays the same activity at every moment. Fibrillation is a dynamic process sustained by the interaction among triggers, susceptible tissue, and autonomic modulation.

Etiology, substrate, and pathophysiology

The pulmonary veins are a particularly important source of impulses capable of initiating fibrillation. Their myocardial sleeves have conduction, refractoriness, and calcium-handling properties that favor ectopic activity. A premature beat may encounter areas that have already recovered and regions that remain refractory, fragment, and activate different pathways. The importance of venous triggers explains the central role of their isolation, but it does not mean that every episode begins in the veins or that they are sufficient to maintain all persistent forms.

Other triggers may arise from the superior vena cava, coronary sinus, atrial walls, left atrial appendage, or structures related to the vein of Marshall. Their importance varies with the patient, disease duration, and previous procedures. Identification of an extrapulmonary source requires relevant electrophysiological documentation; a list of possible sites does not justify preventive ablation of all of them. An organized tachycardia can also degenerate into fibrillation, especially when rapid activation encounters an anisotropic substrate.

At the cellular level, intracellular calcium overload and spontaneous releases from the sarcoplasmic reticulum generate depolarizing currents through the sodium-calcium exchanger. Adrenergic stimulation, activation of calcium/calmodulin-dependent kinase, and altered ryanodine receptors can amplify these events. Afterdepolarizations become effective triggers when they reach threshold and propagate. However, not everything that generates abnormal activity in a single cell is able to overcome the electrical load of the surrounding tissue.

Reentry depends on the relationship among conduction velocity, duration of refractoriness, and the dimensions of the available pathway. Shortened refractoriness or heterogeneous slowing of conduction allows a wavefront to encounter excitable tissue again. In real atrial myocardium, variable thickness, fiber orientation, and discontinuities produce three-dimensional propagation. Multiple wavelets, rotating sources, and endocardial-epicardial dissociation are complementary models for explaining different behaviors; no single mechanistic scheme has been demonstrated for all patients.

Fibrillation progressively modifies its own substrate. Electrical remodeling includes adaptations of ionic currents, reduction of L-type calcium current, and changes in potassium currents that can shorten the action potential. The response is heterogeneous and context-dependent. Some of these changes regress after restoration of rhythm, whereas fibrosis and myocyte loss may persist. The greater tendency to recur after prolonged episodes derives from this interaction, not from a temporal threshold beyond which recovery would be impossible.

Structural remodeling is driven by stretch, inflammation, fibroblast activation, and extracellular matrix deposition. Activation of the renin-angiotensin-aldosterone system, oxidative stress, and profibrotic signaling alter architecture and intercellular communication. Interstitial and replacement fibrosis interrupt myocardial bundles, create slow conduction, and increase dispersion of recovery. Epicardial fat may contribute through infiltration, inflammatory mediators, and autonomic interactions; its relationship with the arrhythmia is not explained simply by the total amount of adipose tissue.

Atrial cardiomyopathy may precede fibrillation, be worsened by it, and persist after its treatment. It includes structural, contractile, electrical, and prothrombotic abnormalities that do not necessarily coincide with dilation. A normally sized atrium may have fibrosis or dysfunction; a dilated atrium may retain some mechanical reserve. Atrial size is therefore a useful marker, but not a complete measure of the substrate nor an isolated criterion for excluding rhythm control.

Arterial hypertension promotes ventricular hypertrophy and diastolic dysfunction, increased filling pressure, and left atrial overload. In mitral stenosis, the pressure load is direct, whereas in mitral regurgitation a combination of volume and pressure overload predominates. Heart failure and fibrillation reinforce each other: congestion stretches the atria, the arrhythmia reduces filling efficiency, and it may accelerate ventricular deterioration. Treating rate alone leaves many of these mechanisms active.

Obesity and obstructive sleep apnea are associated with metabolic abnormalities, inflammation, and intrathoracic pressure swings. Episodes of hypoxia and arousal produce autonomic fluctuations and repeated hemodynamic stress. Diabetes and kidney disease contribute through remodeling, endothelial dysfunction, and comorbidity. Epidemiologic association does not make every treatment equivalent: treating sleep apnea is indicated for its specific benefits, whereas evidence that it invariably reduces fibrillation recurrences is less consistent than some observational studies suggest.

Alcohol, particularly in large amounts or concentrated over short periods, may facilitate arrhythmia initiation and persistence. Autonomic effects, electrolyte abnormalities, myocardial toxicity, and sleep disruption contribute. Thyrotoxicosis, acute infections, pulmonary embolism, ischemia, surgery, and severe systemic stress can also precipitate an episode. The presence of a correctable trigger does not prove that the atrium was normal before the event and does not guarantee absence of recurrence once the acute phase has resolved.

The genetic component includes common variants that modestly alter risk and rarer forms associated with channelopathies or cardiomyopathies. In very young patients, familial clustering, or the presence of conduction disturbances, ventricular arrhythmias, and structural abnormalities, fibrillation may be an early sign of inherited disease. Genetic testing should be guided by the phenotype and accompanied by counseling; a variant of uncertain significance does not establish causality and does not support invasive decisions based on the molecular finding alone.

The autonomic nervous system acts in both directions. Sympathetic activity promotes automaticity and calcium overload; vagal activity shortens atrial refractoriness heterogeneously. Nocturnal or postprandial episodes and exertion-related attacks suggest different modulations, but the distinction between vagal and adrenergic fibrillation is often incomplete. Sleep, training, medications, and heart disease modify the response over time. The individual patient’s history is more informative than an autonomic label used as an exhaustive explanation.

The ventricular response results from the interaction between atrial impulses and nodal conduction, influenced by refractoriness, concealed penetration, and autonomic tone. In the presence of an accessory pathway, this protective filter may be bypassed and conduction may become extremely rapid. In ordinary forms, by contrast, hemodynamic harm arises from rate, irregularity, loss of atrial contribution, and underlying heart disease. Thrombosis adds another pathophysiological layer: stasis in the left atrial appendage, endocardial abnormalities, and activation of coagulation may persist even when the ECG appears temporarily normal.

Classification, clinical manifestations, and special settings

First-diagnosed atrial fibrillation is atrial fibrillation documented for the first time, regardless of its actual duration and symptoms. It is not necessarily the first biological episode: previous attacks may have been silent. Paroxysmal atrial fibrillation terminates within seven days, spontaneously or with intervention; persistent atrial fibrillation continues beyond seven days. Long-standing persistent atrial fibrillation indicates continuous arrhythmia for more than twelve months when rhythm control remains the goal. These definitions describe the observed course and help guide strategy, without replacing assessment of the substrate.

The term permanent expresses the shared decision to accept the arrhythmia and not pursue further attempts to restore sinus rhythm. It is not proof of anatomical irreversibility. If symptoms, therapeutic opportunities, or preferences change, the strategy may be reconsidered. Progression from paroxysmal to persistent fibrillation is not inevitable either: some patients remain stable, others progress, and others improve after rhythm interventions and risk-factor modification. The historical term lone atrial fibrillation is of limited usefulness when it conceals incomplete characterization of the disease.

Arrhythmia burden indicates the amount of time spent in fibrillation during an observed interval. It depends on monitoring duration and cannot be reconstructed accurately from the number of symptomatic episodes alone. One long episode and ten brief episodes may have different consequences, just as the same percentage burden may arise from different temporal distributions. Maximum duration, ventricular rate, and association with functional deterioration complement the quantitative measure. A low burden does not automatically justify discontinuing prophylaxis indicated by clinical risk.

Subclinical atrial fibrillation identified by devices requires rigorous terminology. An atrial high-rate episode is initially an algorithmic detection, not a definitive diagnosis: noise, oversensing, and other tachyarrhythmias can mimic it. After review of the intracardiac or electrocardiographic tracing, atrial fibrillation may be recognized. This population differs from patients with clinically documented arrhythmia in episode duration and absolute risk; results of anticoagulation trials cannot be transferred without considering that difference.

Palpitations may be rapid, irregular, or described as a succession of strong beats and pauses. Perception also depends on the ventricular response and emotional state. Some patients mainly experience fatigue, reduced concentration, or worsening walking capacity; others notice dyspnea during activities previously well tolerated. Absence of palpitations does not exclude a meaningful impact, and improvement after cardioversion may reveal a limitation that had been attributed to age.

The history reconstructs onset, pattern of attacks, duration, frequency, associated factors, and response to treatment. The beginning of symptoms must be distinguished from the last certain documentation of sinus rhythm, especially when cardioversion is being planned. Previous embolic events, bleeding, hypertension, valvular disease, heart failure, kidney disease, thyroid disorders, and cardiac procedures are sought. Prescribed drugs, over-the-counter products, stimulants, and alcohol intake are part of the assessment, together with family history and any intolerance to previous antiarrhythmic drugs.

On physical examination, the pulse is typically irregular and may show a deficit compared with the auscultatory heart rate because some systoles do not generate a perceptible peripheral pulse wave. Variability in filling times changes the intensity of the first heart sound and pulse amplitude. Blood pressure, perfusion, mental status, oxygen saturation, congestion, and valvular murmurs help define urgency and etiology. An apparently regular pulse does not exclude the diagnosis in the presence of a pacemaker or atrioventricular block; marked irregularity alone does not confirm it.

Syncope should not automatically be attributed to atrial fibrillation. It may result from an extremely rapid response, pre-excitation, a conversion pause, sinus node dysfunction, atrioventricular block, or noncardiac causes. Recording the event is decisive when available. A moderately elevated rate in a stable patient does not necessarily explain complete loss of consciousness. Conversely, hypotension, persistent ischemic pain, pulmonary edema, and altered mental status during the arrhythmia require immediate assessment of a causal relationship.

In heart failure, the relationship is bidirectional. Atrial fibrillation may be a consequence of elevated atrial pressures, a cause of arrhythmia-induced cardiomyopathy, or a factor that worsens pre-existing dysfunction. Even a mean rate that is not very high may be harmful because of irregularity and loss of synchronization. In patients with cardiac resynchronization therapy, rapid intrinsic conduction can reduce the percentage of effective biventricular pacing. Device counters should be interpreted together with assessment for fusion and pseudofusion, which may overestimate therapy actually delivered.

Forms associated with acute illness, such as sepsis, pneumonia, and surgery, require treatment of the precipitating factor and subsequent surveillance. Spontaneous return to sinus rhythm does not prove that future risk is absent. During critical illness, however, the immediate benefit of anticoagulation may be uncertain and bleeding risk substantial: the decision cannot be reduced to mechanical application of an outpatient score. After stabilization, recurrence, embolic risk, and the appropriateness of ongoing therapy should be reassessed.

Postoperative atrial fibrillation may be promoted by inflammation, adrenergic activation, volume shifts, and electrolyte disturbances. It is common after cardiac surgery but not always benign; after noncardiac surgery it may signal systemic and atrial vulnerability. The choice among rate control, cardioversion, and thrombotic prevention depends on stability, persistence, type of surgery, and bleeding risk. A prescription initiated during hospitalization should have a date and criteria for reassessment, avoiding both automatic discontinuation and unreviewed continuation.

In the athlete, especially after many years of intense endurance exercise, atrial dilation, vagal modulation, and other adaptations may contribute to susceptibility. Hypertension, sleep disorders, substances, and heart disease still need to be excluded. Therapeutic choices should consider the impact of drugs on performance, the possibility of rapid conduction, and traumatic risk during anticoagulation. Reduction or modification of training can be discussed individually; it does not replace embolic prevention when that is indicated.

In pregnancy, heart disease, thyroid abnormalities, and metabolic factors should be sought because atrial fibrillation is less common than in older populations. Maternal instability and urgent cardioversion require prompt intervention with obstetric, anesthetic, and cardiology coordination. Drug selection considers gestational age, ventricular function, and fetal safety; direct oral anticoagulants are not the usual choice. The antithrombotic regimen also depends on any mechanical prosthetic valves and cannot simply be derived from that used in the nonpregnant adult.

In frail older adults, cognitive impairment, falls, polypharmacy, and difficulty accessing care influence treatment feasibility. Frailty does not mean therapeutic futility, but it requires realistic goals and adherence support. Decisions may prioritize symptoms, independence, and reduction of hospitalizations while maintaining an explicit assessment of embolic risk. Involvement of family members or caregivers is useful when agreed with the patient; simplifying the regimen must not become empirical reduction of anticoagulant doses.

Electrocardiographic diagnosis and integrated assessment

The diagnosis requires interpretable electrical documentation. A twelve-lead ECG can identify the absence of organized P waves, fibrillatory activity, and the ventricular response, while also assessing QRS, QT, pre-excitation, ischemic signs, and conduction disturbances. In single-lead tracings, signal quality and recording duration become particularly important. The thirty-second convention is widely used to document episodes by monitoring; it is not a biological threshold that by itself determines prognosis or the need for anticoagulation.

Fibrillatory waves may be obvious or very low in amplitude, with an appearance that varies among leads. An almost flat baseline does not exclude fibrillation; tremor, movement, and poor electrode contact can instead create similar oscillations. It is useful to compare several leads, look for regular P waves traversing the artifact, and observe the relationship between atrial activity and QRS complexes. Automated devices can flag a suspicion, but clinical interpretation must confirm that the signal actually represents a cardiac rhythm.

The differential diagnosis includes frequent premature atrial contractions, flutter with variable block, multifocal atrial tachycardia, and marked sinus arrhythmia. In multifocal atrial tachycardia, distinct P waves with different morphologies and isoelectric segments can be identified; in flutter, atrial activity retains more regular organization. In very rapid rhythms or degraded signals, this distinction may be difficult. Extending the recording or improving tracing quality is often more useful than relying on RR irregularity as the sole criterion.

An irregular tachycardia with wide QRS complexes requires particular attention. It may represent fibrillation with bundle branch block, cycle-dependent aberrancy, or conduction over an accessory pathway; polymorphic ventricular arrhythmias must also be considered. Extremely short RR intervals and major changes in morphology may suggest pre-excitation. Until this has been reasonably excluded, use of drugs that block only the atrioventricular node may be dangerous. Recognition of this scenario comes before selection of usual pharmacological rate control.

If the resting ECG is normal, ambulatory monitoring should be tailored to event frequency. A short Holter recording may be sufficient for daily symptoms, whereas prolonged recordings, patient-activated devices, or implantable monitors are more suitable for sporadic episodes in selected settings. The aim may be to confirm the diagnosis, correlate symptoms with rhythm, quantify burden, or identify pauses. The report should state the duration that was actually analyzable and any limitations, because absence of arrhythmia during a few hours is not equivalent to exclusion of the disease.

Wearable devices may increase the likelihood of documentation, but photoplethysmography and ECG are not equivalent. An irregular-pulse notification is a screening tool for further evaluation; a valid electrocardiographic tracing may instead document the arrhythmia after competent review. The predictive value of notifications depends on prevalence and signal quality. In people with a low pretest probability, a larger proportion of alerts may be false, and multiplying measurements does not eliminate this problem.

Transthoracic echocardiography assesses ventricular function and dimensions, valvular disease, atrial volume, estimated pressures, and other conditions that modify treatment. During fibrillation, interval variability affects measurements: representative beats or appropriate averages should be used, avoiding conclusions from a single cycle. Ejection fraction may be depressed by tachycardia and should be reassessed after treatment. Atrial volume and strain may contribute to characterization, but they do not replace clinical judgment and do not by themselves define an indication for anticoagulation.

Transesophageal echocardiography is used when thrombi need to be excluded, particularly in the left atrial appendage, before a procedure that restores rhythm or requires left atrial access. Spontaneous echo contrast, sludge, and reduced emptying velocities indicate stasis, although they are not all equivalent to a definite thrombus. Cardiac computed tomography with appropriate acquisitions, including delayed phases when needed, may be an alternative in selected settings. An early filling defect may represent slow flow and should not automatically be interpreted as thrombosis.

Initial laboratory testing generally includes a complete blood count, renal function, electrolytes, and thyroid assessment, with additional testing according to history and context. Liver function is relevant to medications and coagulation; anemia and infection may explain part of a rapid response. Troponin, natriuretic peptides, or investigations for pulmonary embolism should be requested when the presentation warrants them. A modest troponin rise during tachycardia does not automatically identify an acute coronary syndrome, but it also does not justify ignoring symptoms and the clinical probability of ischemia.

Cardiac magnetic resonance helps in selected cases to define cardiomyopathies, ventricular fibrosis, and possible causes of functional deterioration. Quantification of atrial fibrosis requires specialized techniques and has limitations related to the thin atrial wall and lack of standardization. It is not a mandatory test for everyone nor an independent criterion for ablation or anticoagulation. Anatomical computed tomography may be useful for procedural planning, but it should answer a specific question while considering radiation exposure, contrast, and renal function.

Exercise testing can clarify rate control during activity, functional capacity, and symptoms, or contribute to evaluation for ischemia when indicated. It is not required to confirm already documented atrial fibrillation. In patients treated with drugs that slow conduction or alter repolarization, exercise may reveal problems not apparent at rest, but testing should be performed under appropriate conditions. The rate measured in the clinic does not necessarily describe what occurs during usual activities.

Diagnostic evaluation concludes with an operational characterization: temporal pattern, observed burden, symptoms, heart disease, modifiable factors, thrombotic risk, bleeding risk, and treatment preferences. Symptom classification may distinguish no symptoms, mild symptoms, significant limitation, and inability to perform usual activities. These elements should be reassessed over time. A label recorded years earlier does not necessarily describe the current patient, especially after a stroke, development of heart failure, or a change in renal function.

Thromboembolic risk and antithrombotic prevention

Stroke prevention is an objective in its own right, separate from symptom relief. Paroxysmal atrial fibrillation is not automatically risk-free, and a well-controlled rate does not protect against atrial thrombosis. The decision on anticoagulation considers clinical risk, contraindications, modifiable bleeding risk, and informed preferences. Stratification tools help make the decision reproducible, but they provide population estimates and do not predict an individual event with certainty.

The 2024 European guidelines use CHA2DS2-VA, assigning one point for heart failure, hypertension, diabetes, vascular disease, and age 65 to 74 years; two points for age at least 75 years and for previous stroke, transient ischemic attack, or arterial embolism. The two age categories are mutually exclusive. With a score of at least two, anticoagulation is recommended; with one point, it should be considered after individual assessment. Sex is not included in this score, unlike CHA2DS2-VASc, which is still used in other recommendations and in many studies.

CHA2DS2-VASc adds female sex, which should be interpreted as a risk modifier rather than an isolated indication for treatment. In US recommendations, the principal reference is estimated annual risk, with anticoagulation recommended when sufficiently high and reasonable in some intermediate-risk situations. Clinical documentation should specify which tool was used. Adding or subtracting points without recognizing the version can produce inconsistent decisions, especially in women and in patients near the treatment threshold.

There are conditions in which general scores represent risk poorly. Atrial fibrillation in hypertrophic cardiomyopathy or cardiac amyloidosis requires specific considerations; significant mitral stenosis and mechanical prosthetic valves belong to dedicated antithrombotic pathways. Previous atrial thrombus, marked appendage dysfunction, and an embolic history require attention even when the demographic profile appears favorable. These factors do not justify invented thresholds, but they prevent a purely arithmetic application of risk assessment.

Direct oral anticoagulants are generally preferred to vitamin K antagonists in eligible patients. Apixaban, dabigatran, edoxaban, and rivaroxaban differ in elimination, interactions, dosing frequency, and dose-reduction criteria. Choice considers renal function, age, weight, adherence, and concomitant medications. Mechanical prosthetic valves and moderate or severe mitral stenosis instead require vitamin K antagonists. Other valvular lesions or a bioprosthesis should not automatically be treated as equivalent to these exclusions.

Dosing must follow the drug-specific criteria and the applicable authorization. Empirical dose reduction because of fear of bleeding may reduce protection without guaranteeing a bleeding benefit. The renal-function estimate used for dosing should be consistent with that specified in trials and product information, often creatinine clearance according to Cockcroft-Gault. Dehydration, infection, weight changes, and deterioration of renal function require reassessment; a prescription that was correct initially may become inappropriate months later.

With vitamin K antagonists, the quality of INR control determines efficacy and safety. For routine prevention in atrial fibrillation, the usual range is 2.0-3.0, whereas some mechanical prosthetic valves require specific targets. Interactions, unstable diet, intercurrent illness, and difficulty with monitoring may reduce time in therapeutic range. Switching to a direct agent, when possible, should be planned according to INR and the characteristics of the drug, without arbitrary periods of overlap or lack of protection.

Assessment of bleeding risk is used primarily to correct uncontrolled hypertension, avoidable drug combinations, alcohol use, anemia, and bleeding lesions. A high score alone is not a reason to deny anticoagulation to someone who may benefit. Antiplatelet agents and nonsteroidal anti-inflammatory drugs increase risk and require an explicit indication. Falls should be addressed by intervening on causes and environment; a history of major bleeding instead requires assessment of site, reversibility, and likelihood of recurrence.

Aspirin does not replace anticoagulation for embolic prevention in atrial fibrillation when anticoagulation is indicated. Combination with an anticoagulant may be necessary after an acute coronary syndrome or percutaneous intervention, but it increases bleeding and should have a justified duration and composition. In stable coronary disease without a current need for antiplatelet therapy, continued combination therapy is not automatic. The plan should specify when each drug is to be stopped, preventing a temporary regimen from becoming permanent through inertia.

Before planned cardioversion, whether electrical or pharmacological, the risk of mobilizing pre-existing thrombi must be addressed. The 2024 European recommendations take a cautious approach when duration exceeds twenty-four hours or is unknown: therapeutic anticoagulation for at least three weeks or suitable imaging to exclude thrombus before earlier cardioversion. Actual adherence to direct agents must be verified; a prescription or a generic statement that the medication was taken does not replace reconstruction of missed doses.

After cardioversion, anticoagulation is generally continued for at least four weeks because mechanical atrial recovery may lag behind electrical recovery. Limited exceptions concern patients at genuinely very low risk with certainly brief duration and require assessment consistent with the recommendations being followed. Continued therapy thereafter depends on thromboembolic risk and not only on the presence of sinus rhythm. If a thrombus is documented, elective cardioversion is postponed, adequate therapy is ensured, and reassessment is scheduled.

In hemodynamic instability attributable to the arrhythmia, urgent cardioversion should not be delayed to complete weeks of anticoagulation or a transesophageal examination. Antithrombotic protection is started as soon as practicable according to risk and contraindications. This emergency pathway does not mean embolic risk is absent; it means hemodynamic urgency takes precedence over the ability to follow the elective sequence. After stabilization, prophylaxis and reassessment of treatment duration remain necessary.

During atrial fibrillation ablation, rigorous periprocedural anticoagulation is used, generally without prolonged interruption of oral treatment and with intraprocedural anticoagulation. After the procedure, European recommendations call for at least two months of therapy regardless of baseline risk; US recommendations indicate at least three months. Continuation beyond this period has traditionally been guided by individual risk because silent recurrences, atrial substrate, and other thrombotic factors may persist despite clinical success.

The randomized ALONE-AF trial, published in 2025, studied 840 patients with no documented recurrence for at least one year after ablation and with at least one non-sex-related risk factor. Discontinuation of anticoagulation produced a more favorable composite outcome of stroke, systemic embolism, or major bleeding than continuation. The result applies to a selected population and to an outcome combining both efficacy and safety; it does not show that ablation abolishes embolic risk in every patient, nor does it justify immediate discontinuation after the procedure.

In the OCEAN trial, published in print in 2026, 1,284 patients who had undergone successful ablation at least one year earlier were assigned to rivaroxaban or aspirin. Rivaroxaban did not significantly reduce the composite outcome including stroke, systemic embolism, and new silent embolic cerebral infarctions defined by the protocol. The rarity of events and width of the confidence interval limit conclusions of equivalence. The comparison does not make aspirin a universal substitute for anticoagulation in atrial fibrillation and does not resolve management of patients at very high risk.

These new data support a more individualized discussion after durable ablation success, considering patient selection, monitoring, residual risk, and the ability to restart therapy. A documented specialist decision must be distinguished from automatic discontinuation based on disappearance of symptoms. Intermittent anticoagulation triggered by a watch or a single detected episode cannot be assumed to be a routinely validated strategy for everyone: embolic events and arrhythmia do not always have an immediate temporal relationship.

For subclinical atrial fibrillation, ARTESiA showed that apixaban reduced stroke or systemic embolism compared with aspirin, accompanied by more major bleeding. NOAH-AFNET 6, in patients with atrial high-rate episodes, did not demonstrate a significant benefit of edoxaban on the primary efficacy outcome and showed a safety cost. The populations and designs were not identical. Episode duration, baseline risk, and bleeding vulnerability should therefore guide selection, avoiding treatment of every brief detection as persistent clinical atrial fibrillation.

Left atrial appendage closure may be considered in selected patients, particularly when long-term anticoagulant therapy is not feasible or when the risk-benefit balance favors a mechanical strategy. It does not eliminate every source of stroke and carries procedural risks, device-related thrombosis, and possible residual leaks. The initial antithrombotic regimen must also be compatible with bleeding risk. Surgical closure performed concomitantly with cardiac surgery should not automatically be interpreted as permission to stop otherwise indicated therapy.

Perioperative anticoagulation management depends on the bleeding risk of the procedure, renal function, the drug, and urgency. Many minor procedures can be performed with minimal interruption or without discontinuation according to the relevant protocol; higher-risk procedures require different timing. Heparin bridging is not routinely necessary in patients treated with direct agents and may increase bleeding. Even with vitamin K antagonists it is not an automatic choice: mechanical prosthetic valves and particularly important thrombotic conditions require dedicated assessment.

Major bleeding requires control of the source, hemodynamic support, reconstruction of the last dose, and assessment of whether anticoagulant effect is likely to persist. Common coagulation tests do not reliably measure the activity of all direct agents. In severe cases, specific antidotes or factor concentrates may be required according to the drug, availability, and applicable protocol. Reversal also carries thrombotic risk; after hemostasis, resumption should be planned on the basis of the indication for anticoagulation and the likelihood of recurrent bleeding.

Advanced kidney disease makes the balance more difficult because it increases both thrombotic events and bleeding and alters drug exposure. Evidence in dialysis patients is less robust than in the populations included in the major registration trials. It is incorrect to regard all direct agents as equivalent or to extend a reduced dose automatically to every level of renal impairment. The decision should compare available data, local authorizations, and patient characteristics, with frequent reassessment when acute changes occur.

Rate control, rhythm restoration, and ablation

Therapeutic choice begins with hemodynamic stability and the search for correctable factors. Rapid atrial fibrillation may be the main cause of shock or pulmonary edema, but it may also accompany sepsis, hypovolemia, or respiratory failure. In the latter settings, abruptly slowing a compensatory response without treating the precipitant may worsen perfusion. Oxygenation, volume status, electrolytes, and pain should be assessed together with rhythm, without waiting for a single intervention to resolve a multifactorial condition.

If the arrhythmia causes instability, synchronized electrical cardioversion is the treatment of choice. Synchronization with the QRS reduces the risk of delivering a shock during the vulnerable ventricular phase; sedation and respiratory support are arranged when compatible with urgency. Pad position, skin contact, and adequate energy influence efficacy. Failure requires technical verification and reassessment of the setting, not an indefinite sequence of shocks without correction of hypoxia, imbalances, or factors promoting immediate recurrence.

In a stable patient, rate control reduces symptoms and ventricular overload. A relatively lenient initial target, often below 110 beats per minute at rest, may be appropriate if symptoms and ventricular function are satisfactory. It is not a universal goal: arrhythmia-induced cardiomyopathy, persistent heart failure, ischemia, or the need to ensure resynchronization may require tighter control. Rates during exercise and sleep should also be considered because a single measurement does not describe total exposure.

Beta-blockers are particularly useful when adrenergic activation, ischemia, or other concomitant indications predominate. Choice and titration depend on blood pressure, ventricular function, and respiratory conditions. In acutely decompensated heart failure, caution is needed when introducing or rapidly increasing therapy, whereas well-tolerated chronic treatment should not be changed without assessing the overall clinical picture. Bradycardia, hypotension, fatigue, and reduced exercise response may limit treatment even when the resting rate appears ideal.

Diltiazem and verapamil slow nodal conduction and may be effective in patients with preserved systolic function and adequate blood pressure. Their negative inotropic effect makes them inappropriate in significant systolic dysfunction, particularly with an ejection fraction no greater than 40%, and in relevant acute heart failure. Combining them with beta-blockers increases the risk of bradycardia and block and requires surveillance. Availability of several nodal agents does not justify progressive combinations without a defined clinical objective.

Digoxin can contribute to rate control, especially at rest and in heart failure, or supplement an insufficient regimen. It is less effective when adrenergic tone is high. Renal elimination, age, body mass, potassium, and interactions influence toxicity risk; plasma measurement is useful when indicated but must be interpreted in relation to timing of the dose. Nausea, confusion, visual disturbances, and new arrhythmias may indicate accumulation and should not automatically be attributed to heart disease.

Intravenous amiodarone may be used in selected settings, such as critically ill patients or those with ventricular dysfunction in whom other options are unsuitable. It may also convert the rhythm, making embolic risk relevant. It is not a harmless solution for chronic rate control: thyroid, hepatic, and pulmonary toxicity, interactions, and bradycardia limit its use. The intended duration and availability of alternatives should be made explicit when it is started during hospitalization.

In pre-excited atrial fibrillation, beta-blockers, digoxin, verapamil, diltiazem, and adenosine may favor conduction over the accessory pathway and should not be used as routine nodal therapy; intravenous amiodarone should also be avoided in this setting. If the patient is unstable, cardioversion is performed; if stable, drugs appropriate for the accessory pathway, such as procainamide or ibutilide according to availability and contraindications, may be used in a monitored setting. Definitive management requires assessment for pathway ablation.

Rhythm control is not reserved for failure of rate control. It may be indicated for symptoms, functional improvement, suspected arrhythmia-induced cardiomyopathy and, in selected patients, reduction of cardiovascular events. The EAST-AFNET 4 trial supported an early strategy in patients with a recent diagnosis and associated cardiovascular conditions. The benefit concerns an integrated pathway including drugs, cardioversion, possible ablation, and appropriate embolic prevention; it does not show that every newly discovered episode requires an immediate invasive procedure.

Pharmacological cardioversion is an option in stable patients when the drug, heart disease, and episode duration permit it. Flecainide and propafenone are reserved for patients without relevant ischemic or significant structural heart disease and require attention to conduction and ventricular function. Possible organization into flutter with 1:1 conduction generally makes appropriate nodal protection necessary. Ibutilide carries a risk of QT prolongation and torsades de pointes; amiodarone may act more slowly but can be used in some heart diseases in which class IC drugs are unsuitable.

The pill-in-the-pocket strategy with an oral antiarrhythmic is intended for carefully selected patients with recognizable, infrequent, well-tolerated episodes. Safety of the first dose should be verified in a monitored setting, and the patient must know when not to take the drug and when to seek assistance. It is not a generic prescription for any palpitation. The strategy does not replace assessment for anticoagulation and cannot be applied to an episode of uncertain duration without considering the risk associated with conversion.

For maintenance of sinus rhythm, choice depends first on safety and then on efficacy. Flecainide and propafenone require absence of the relevant structural and ischemic contraindications; sotalol requires monitoring of QT, renal function, and bradycardia. Dronedarone is not indicated in permanent atrial fibrillation or in patients with advanced or recently decompensated heart failure. Amiodarone is effective but burdened by cumulative toxicity, whereas dofetilide, where available, requires monitored initiation and renal dose adjustment. Drug availability differs among countries.

Surveillance of antiarrhythmic drugs includes ECG, renal function, and electrolytes according to the drug, in addition to specific testing for extracardiac toxicity. Significant QRS widening with class IC drugs, excessive QT prolongation, or new bradycardia require reassessment. Interactions with antibiotics, psychotropic agents, and other medications may change risk without changing the antiarrhythmic dose. A pacemaker protects against some consequences of bradycardia but does not eliminate organ toxicity or every form of proarrhythmia.

Catheter ablation is an effective therapy for reducing recurrences and symptoms, offered after drug inefficacy or intolerance or as first-line treatment in selected patients. Candidacy depends on the form and duration of fibrillation, atrial size and function, heart disease, comorbidities, and expectations. Chronological age is not the only criterion, and the likelihood of requiring more than one procedure should be discussed. In patients with ventricular dysfunction attributable at least in part to the arrhythmia, potential benefit may extend beyond relief of palpitations.

The cornerstone is pulmonary vein isolation, which interrupts propagation of triggers toward the atrium. The procedure requires venous access, transseptal passage, and verification of electrical block according to the technique used. Simple termination of fibrillation during energy delivery is not equivalent to durable isolation. Venous reconnection, extrapulmonary triggers, and progression of the substrate may explain recurrence; during a repeat procedure, the mechanism should be reassessed rather than assuming that every episode has the same cause.

Radiofrequency produces point-by-point lesions and requires attention to contact, stability, power, duration, and continuity. Cryoballoon ablation creates lesions by cooling and is used mainly for pulmonary vein isolation, with specific monitoring of the phrenic nerve and occlusion. Pulsed-field ablation uses electroporation and has a different tissue-selectivity profile. No technology eliminates risks related to vascular access, transseptal puncture, embolism, or tamponade; team experience and appropriate patient selection remain decisive.

Pulsed-field ablation reduces some concerns related to collateral thermal injury but should not be described as complication-free. Relevant issues include hemolysis and possible kidney injury under particular exposure conditions, coronary spasm in sensitive locations, and risks specific to the platform. Energy, number of applications, and anatomy are not interchangeable among systems. Results from one device cannot automatically be extended to all others, and adoption of a new technology does not replace verification of the electrical endpoint.

In persistent fibrillation, adding extra-pulmonary-vein lesions does not provide a uniform benefit. Lines, posterior-wall isolation, treatment of low-voltage areas, or targeting of specific sources require a rationale based on patient characteristics and data supporting the strategy. Incomplete lesions may create iatrogenic organized tachycardias. A more extensive procedure is not necessarily better: residual atrial function, collateral injury, and the possibility of new circuits must be considered alongside efficacy.

Surgical or hybrid procedures may be indicated during other cardiac operations or in selected patients with complex persistent arrhythmia. Depending on the case, they combine epicardial and endocardial approaches and may treat areas difficult to reach with a single modality. They require balancing greater invasiveness against expected benefit. The decision about appendage closure and the decision about arrhythmia treatment are related but distinct, as is the subsequent need for anticoagulation.

When rate control remains inadequate and rhythm control is not feasible or has failed, atrioventricular junction ablation combined with pacing can provide stable regularization of ventricular activation. It does not eliminate atrial fibrillation or embolic risk and requires a reliable pacing strategy. Pacing type, ventricular function, and expected pacing burden should be considered before the procedure; resynchronization or conduction-system pacing may be preferable to right ventricular pacing alone in appropriate settings.

Treatment of the modifiable substrate accompanies all strategies. Sustained weight loss when indicated, blood pressure control, tailored physical activity, reduction of alcohol, and smoking cessation may improve the course. US recommendations propose, in relevant patients with excess weight, an ideal target of at least 10% weight loss and a progressive aerobic program that may reach 210 minutes per week. These goals should be adapted to frailty and heart disease, not used as rigid prescriptions for every patient. Treatment of heart failure and valvular disease remains essential even when rhythm improves.

In minimally symptomatic persistent atrial fibrillation, cardioversion may also serve as a functional assessment: comparing sinus rhythm with fibrillation helps identify benefits that were not previously perceived. This requires antithrombotic protection and a subsequent strategy because isolated conversion in an advanced substrate may be followed by rapid recurrence. If no clinical benefit emerges and rhythm maintenance carries disproportionate risks, accepting the arrhythmia may be reasonable. The decision should remain shared and revisable.

A recurrence after cardioversion may occur immediately because of a new trigger or after days or weeks because the substrate persists. The distinction may guide drug preparation, choice of ablation, and correction of precipitants. Repeating cardioversion may be useful within a defined pathway, but it does not by itself solve a sequence of relapses if the maintenance strategy does not change. The clinical costs of repeated sedation, hospitalizations, and periods of therapeutic instability should also be considered.

In patients with heart failure with reduced ejection fraction, ablation may improve function and, in selected populations, major clinical outcomes. The magnitude of benefit depends on the reversible component of cardiomyopathy, arrhythmia duration, and underlying disease. Marked ventricular fibrosis or end-stage heart disease may limit benefit without making every procedure futile. Comparison with optimized pharmacological therapy and, when relevant, junction ablation with pacing should be individualized rather than based on ejection fraction alone.

Thyrotoxicosis requires control of the endocrine disorder in addition to the ventricular response. Spontaneous conversion may occur after restoration of euthyroidism, but arrhythmia duration and substrate modify the probability. Amiodarone complicates the picture because it may be therapeutically useful in some settings while also inducing thyroid dysfunction. Management should coordinate cardiology and endocrinology, distinguish forms of toxicity, and avoid automatically stopping or continuing the drug in patients who depend on it for arrhythmia control.

Caffeine should not be universally prohibited in usual amounts solely because atrial fibrillation has been diagnosed, unless there is a convincing individual relationship with symptoms. Energy drinks, combinations with stimulants, and large quantities are a different issue. Likewise, supplements or electrolyte replacement are not indiscriminately indicated in the absence of deficiency. Lifestyle prevention is more effective when it focuses on documented, modifiable factors, avoiding unnecessary restrictions that make the pathway difficult to sustain.

Complications, prognosis, and long-term surveillance

Prognosis depends on overall cardiovascular disease as well as rhythm. Age, heart failure, renal function, previous embolic events, valvular disease, and frailty modify outcomes. Atrial fibrillation may be both a causal factor and a marker of advanced disease. Reducing arrhythmia burden is useful, but it does not necessarily normalize mortality, stroke risk, or functional capacity; each objective should be assessed with appropriate measures.

Arrhythmia-induced cardiomyopathy should be suspected when ventricular dysfunction and fibrillation coexist, especially with a rapid response or temporally related deterioration. Recovery after arrhythmia control retrospectively supports a causal component, but it may be incomplete in the presence of fibrosis or pre-existing heart disease. Heart-failure therapy should not be stopped automatically as soon as ejection fraction improves. Recurrence may cause more rapid deterioration, making a plan for early recognition and intervention necessary.

Ischemic stroke associated with atrial fibrillation may be disabling and is sometimes the first manifestation. The presence of the arrhythmia does not prove that every stroke is cardioembolic: atherosclerosis and small-vessel disease may coexist. After an event, timing of initiation or resumption of anticoagulation depends on infarct extent, hemorrhagic transformation, imaging, and neurological assessment. If the event occurs during therapy, adherence, dose, interactions, and alternative mechanisms should be checked before the regimen is changed empirically.

Cognitive decline is associated with atrial fibrillation through multiple pathways, including clinical strokes, silent lesions, vascular comorbidity, and possible perfusion abnormalities. The association does not justify automatically attributing cognitive impairment to the arrhythmia or promising reversibility with ablation. Vascular prevention, adherence, and comorbidity management remain valuable even when an exclusive link between rhythm and cognition cannot be demonstrated.

After cardioversion, pauses and bradycardia may emerge because of sinus node dysfunction, tachycardia-related suppression, or medications. The duration of a pause alone does not describe the entire risk: symptoms, persistence, medications, and escape rhythm are decisive. A brief recovery phase is not necessarily an indication for a pacemaker; symptomatic episodes or significant conduction disease instead require a dedicated pathway. An attempt to maintain rhythm may reveal nodal disease that had previously been masked.

Complications of ablation include bleeding and vascular injury, tamponade, embolism, phrenic nerve injury and, with some techniques or locations, esophageal injury and pulmonary vein stenosis. Their likelihood depends on technology, anatomy, and procedure. Dyspnea, significant chest pain, syncope, or neurological signs in the subsequent period should not be dismissed as normal recovery. The patient should receive understandable instructions about which symptoms require urgent contact and how to reach the center.

Atrioesophageal fistula is rare but potentially fatal and may present some time after the procedure with fever, pain, dysphagia, or neurological manifestations. When suspected, urgent assessment with appropriate imaging, generally contrast-enhanced computed tomography, and specialist involvement are required. An initially negative examination does not always exclude the problem if suspicion remains high. Endoscopy with air insufflation may be dangerous and should not become the automatic initial investigation. This complication must be distinguished from common postprocedural chest discomfort.

Early recurrences after ablation may reflect inflammation, edema, and lesion healing, but also reconnection or persistent substrate. The 2024 consensus proposes an eight-week blanking period for standardized outcome assessment. This does not mean ignoring prolonged episodes, severe symptoms, or heart failure during this interval. Temporary drugs and cardioversion may be appropriate; the decision to repeat ablation immediately should be individualized because not all early recurrences predict lasting failure.

During follow-up, ECG and monitoring are tailored to symptoms, risk, and therapeutic decisions. After ablation, asymptomatic episodes may become more frequent relative to perceived episodes, so subjective well-being does not prove complete absence of arrhythmia. Success should be described by specifying duration of control, medication use, monitoring method, and reduction in burden. A single brief episode and a return to nearly continuous fibrillation do not have the same meaning, even if both may satisfy a recurrence definition used in trials.

Periodic reassessment includes embolic risk, bleeding, renal function, blood pressure, weight, and drug tolerability. Aging or a new diagnosis of diabetes may change the indication for anticoagulation without any worsening of rhythm. Conversely, initially effective antiarrhythmic therapy may become hazardous because of renal failure or interactions. Decisions should be updated and communicated also to professionals managing surgical or dental procedures or new prescriptions.

Quality of life requires a measure distinct from the simple presence of sinus rhythm. Sleep, episode-related anxiety, ability to work, and social participation may improve even with incomplete reduction in burden. Persistent fatigue after electrical success requires evaluation for anemia, deconditioning, heart failure, or drug effects. Involving the patient in choosing goals helps avoid both overtreatment of a tracing and undertreatment of substantial limitation.

Durable management therefore integrates rhythm control and risk control, without assuming that one replaces the other. Embolic prevention should be maintained or reconsidered according to explicit criteria; treatment of comorbidities continues even after ablation; and any decision to accept permanent atrial fibrillation should be accompanied by adequate ventricular and functional control. Prognosis improves when the pathway remains adaptable to the disease and the patient’s priorities rather than becoming fixed on a decision made at the first episode.